mirror of
https://github.com/msberends/AMR.git
synced 2025-01-30 18:24:38 +01:00
(v2.1.1.9134) add Gamma to WISCA documentation
This commit is contained in:
parent
2561494e06
commit
e740aa691b
@ -1,5 +1,5 @@
|
||||
Package: AMR
|
||||
Version: 2.1.1.9133
|
||||
Version: 2.1.1.9134
|
||||
Date: 2025-01-27
|
||||
Title: Antimicrobial Resistance Data Analysis
|
||||
Description: Functions to simplify and standardise antimicrobial resistance (AMR)
|
||||
|
2
NEWS.md
2
NEWS.md
@ -1,4 +1,4 @@
|
||||
# AMR 2.1.1.9133
|
||||
# AMR 2.1.1.9134
|
||||
|
||||
*(this beta version will eventually become v3.0. We're happy to reach a new major milestone soon, which will be all about the new One Health support! Install this beta using [the instructions here](https://msberends.github.io/AMR/#latest-development-version).)*
|
||||
|
||||
|
@ -1,6 +1,6 @@
|
||||
Metadata-Version: 2.2
|
||||
Name: AMR
|
||||
Version: 2.1.1.9133
|
||||
Version: 2.1.1.9134
|
||||
Summary: A Python wrapper for the AMR R package
|
||||
Home-page: https://github.com/msberends/AMR
|
||||
Author: Matthijs Berends
|
||||
|
Binary file not shown.
BIN
PythonPackage/AMR/dist/amr-2.1.1.9133.tar.gz
vendored
BIN
PythonPackage/AMR/dist/amr-2.1.1.9133.tar.gz
vendored
Binary file not shown.
BIN
PythonPackage/AMR/dist/amr-2.1.1.9134.tar.gz
vendored
Normal file
BIN
PythonPackage/AMR/dist/amr-2.1.1.9134.tar.gz
vendored
Normal file
Binary file not shown.
@ -2,7 +2,7 @@ from setuptools import setup, find_packages
|
||||
|
||||
setup(
|
||||
name='AMR',
|
||||
version='2.1.1.9133',
|
||||
version='2.1.1.9134',
|
||||
packages=find_packages(),
|
||||
install_requires=[
|
||||
'rpy2',
|
||||
|
@ -188,15 +188,15 @@
|
||||
#'
|
||||
#' ### Plotting
|
||||
#'
|
||||
#' All types of antibiograms as listed above can be plotted (using [ggplot2::autoplot()] or base \R's [plot()] and [barplot()]).
|
||||
#' All types of antibiograms as listed above can be plotted (using [ggplot2::autoplot()] or base \R's [plot()] and [barplot()]). As mentioned above, the numeric values of an antibiogram are stored in a long format as the [attribute][attributes()] `long_numeric`. You can retrieve them using `attributes(x)$long_numeric`, where `x` is the outcome of [antibiogram()] or [wisca()].
|
||||
#'
|
||||
#' THe outcome of [antibiogram()] can also be used directly in R Markdown / Quarto (i.e., `knitr`) for reports. In this case, [knitr::kable()] will be applied automatically and microorganism names will even be printed in italics at default (see argument `italicise`).
|
||||
#' The outcome of [antibiogram()] can also be used directly in R Markdown / Quarto (i.e., `knitr`) for reports. In this case, [knitr::kable()] will be applied automatically and microorganism names will even be printed in italics at default (see argument `italicise`).
|
||||
#'
|
||||
#' You can also use functions from specific 'table reporting' packages to transform the output of [antibiogram()] to your needs, e.g. with `flextable::as_flextable()` or `gt::gt()`.
|
||||
#'
|
||||
#' @section Why Use WISCA?:
|
||||
#'
|
||||
#' WISCA, as outlined by Barbieri *et al.* (\doi{10.1186/s13756-021-00939-2}), stands for Weighted-Incidence Syndromic Combination Antibiogram, which estimates the probability of adequate empirical antimicrobial regimen coverage for specific infection syndromes. This method leverages a Bayesian hierarchical logistic regression framework with random effects for pathogens and regimens, enabling robust estimates in the presence of sparse data.
|
||||
#' WISCA, as outlined by Bielicki *et al.* (\doi{10.1093/jac/dkv397}), stands for Weighted-Incidence Syndromic Combination Antibiogram, which estimates the probability of adequate empirical antimicrobial regimen coverage for specific infection syndromes. This method leverages a Bayesian hierarchical logistic regression framework with random effects for pathogens and regimens, enabling robust estimates in the presence of sparse data.
|
||||
#'
|
||||
#' The Bayesian model assumes conjugate priors for parameter estimation. For example, the coverage probability \eqn{\theta} for a given antimicrobial regimen is modelled using a Beta distribution as a prior:
|
||||
#'
|
||||
@ -210,16 +210,26 @@
|
||||
#'
|
||||
#' \deqn{\theta | y \sim \text{Beta}(\alpha_0 + y, \beta_0 + n - y)}
|
||||
#'
|
||||
#' Pathogen incidence, representing the proportion of infections caused by different pathogens, is modelled using a Dirichlet distribution, which is the natural conjugate prior for multinomial outcomes. The Dirichlet distribution is parameterised by a vector of concentration parameters \eqn{\alpha}, where each \eqn{\alpha_i} corresponds to a specific pathogen. The prior is typically chosen to be uniform (\eqn{\alpha_i = 1}), reflecting an assumption of equal prior probability across pathogens.
|
||||
#'
|
||||
#' The posterior distribution of pathogen incidence is then given by:
|
||||
#'
|
||||
#' \deqn{\text{Dirichlet}(\alpha_1 + n_1, \alpha_2 + n_2, \dots, \alpha_K + n_K)}
|
||||
#'
|
||||
#' where \eqn{n_i} is the number of infections caused by pathogen \eqn{i} observed in the data. For practical implementation, pathogen incidences are sampled from their posterior using normalised Gamma-distributed random variables:
|
||||
#'
|
||||
#' \deqn{x_i \sim \text{Gamma}(\alpha_i + n_i, 1)}
|
||||
#' \deqn{p_i = \frac{x_i}{\sum_{j=1}^K x_j}}
|
||||
#'
|
||||
#' where \eqn{x_i} represents unnormalised pathogen counts, and \eqn{p_i} is the normalised proportion for pathogen \eqn{i}.
|
||||
#'
|
||||
#' For hierarchical modelling, pathogen-level effects (e.g., differences in resistance patterns) and regimen-level effects are modelled using Gaussian priors on log-odds. This hierarchical structure ensures partial pooling of estimates across groups, improving stability in strata with small sample sizes. The model is implemented using Hamiltonian Monte Carlo (HMC) sampling.
|
||||
#'
|
||||
#' Stratified results can be provided based on covariates such as age, sex, and clinical complexity (e.g., prior antimicrobial treatments or renal/urological comorbidities) using `dplyr`'s [group_by()] as a pre-processing step before running [wisca()]. In this case, posterior odds ratios (ORs) are derived to quantify the effect of these covariates on coverage probabilities:
|
||||
#'
|
||||
#' \deqn{\text{OR}_{\text{covariate}} = \frac{\exp(\beta_{\text{covariate}})}{\exp(\beta_0)}}
|
||||
#'
|
||||
#' By combining empirical data with prior knowledge, WISCA overcomes the limitations
|
||||
#' of traditional combination antibiograms, offering disease-specific, patient-stratified
|
||||
#' estimates with robust uncertainty quantification. This tool is invaluable for antimicrobial
|
||||
#' stewardship programs and empirical treatment guideline refinement.
|
||||
#' By combining empirical data with prior knowledge, WISCA overcomes the limitations of traditional combination antibiograms, offering disease-specific, patient-stratified estimates with robust uncertainty quantification. This tool is invaluable for antimicrobial stewardship programs and empirical treatment guideline refinement.
|
||||
#'
|
||||
#' @source
|
||||
#' * Bielicki JA *et al.* (2016). **Selecting appropriate empirical antibiotic regimens for paediatric bloodstream infections: application of a Bayesian decision model to local and pooled antimicrobial resistance surveillance data** *Journal of Antimicrobial Chemotherapy* 71(3); \doi{10.1093/jac/dkv397}
|
||||
|
@ -1,6 +1,6 @@
|
||||
This knowledge base contains all context you must know about the AMR package for R. You are a GPT trained to be an assistant for the AMR package in R. You are an incredible R specialist, especially trained in this package and in the tidyverse.
|
||||
|
||||
First and foremost, you are trained on version 2.1.1.9133. Remember this whenever someone asks which AMR package version you’re at.
|
||||
First and foremost, you are trained on version 2.1.1.9134. Remember this whenever someone asks which AMR package version you’re at.
|
||||
|
||||
Below are the contents of the file, the file, and all the files (documentation) in the package. Every file content is split using 100 hypens.
|
||||
----------------------------------------------------------------------------------------------------
|
||||
@ -1845,9 +1845,9 @@ Note that for types 2 and 3 (Combination Antibiogram and Syndromic Antibiogram),
|
||||
|
||||
\subsection{Plotting}{
|
||||
|
||||
All types of antibiograms as listed above can be plotted (using \code{\link[ggplot2:autoplot]{ggplot2::autoplot()}} or base \R's \code{\link[=plot]{plot()}} and \code{\link[=barplot]{barplot()}}).
|
||||
All types of antibiograms as listed above can be plotted (using \code{\link[ggplot2:autoplot]{ggplot2::autoplot()}} or base \R's \code{\link[=plot]{plot()}} and \code{\link[=barplot]{barplot()}}). As mentioned above, the numeric values of an antibiogram are stored in a long format as the \link[=attributes]{attribute} \code{long_numeric}. You can retrieve them using \code{attributes(x)$long_numeric}, where \code{x} is the outcome of \code{\link[=antibiogram]{antibiogram()}} or \code{\link[=wisca]{wisca()}}.
|
||||
|
||||
THe outcome of \code{\link[=antibiogram]{antibiogram()}} can also be used directly in R Markdown / Quarto (i.e., \code{knitr}) for reports. In this case, \code{\link[knitr:kable]{knitr::kable()}} will be applied automatically and microorganism names will even be printed in italics at default (see argument \code{italicise}).
|
||||
The outcome of \code{\link[=antibiogram]{antibiogram()}} can also be used directly in R Markdown / Quarto (i.e., \code{knitr}) for reports. In this case, \code{\link[knitr:kable]{knitr::kable()}} will be applied automatically and microorganism names will even be printed in italics at default (see argument \code{italicise}).
|
||||
|
||||
You can also use functions from specific 'table reporting' packages to transform the output of \code{\link[=antibiogram]{antibiogram()}} to your needs, e.g. with \code{flextable::as_flextable()} or \code{gt::gt()}.
|
||||
}
|
||||
@ -1855,7 +1855,7 @@ You can also use functions from specific 'table reporting' packages to transform
|
||||
\section{Why Use WISCA?}{
|
||||
|
||||
|
||||
WISCA, as outlined by Barbieri \emph{et al.} (\doi{10.1186/s13756-021-00939-2}), stands for Weighted-Incidence Syndromic Combination Antibiogram, which estimates the probability of adequate empirical antimicrobial regimen coverage for specific infection syndromes. This method leverages a Bayesian hierarchical logistic regression framework with random effects for pathogens and regimens, enabling robust estimates in the presence of sparse data.
|
||||
WISCA, as outlined by Bielicki \emph{et al.} (\doi{10.1093/jac/dkv397}), stands for Weighted-Incidence Syndromic Combination Antibiogram, which estimates the probability of adequate empirical antimicrobial regimen coverage for specific infection syndromes. This method leverages a Bayesian hierarchical logistic regression framework with random effects for pathogens and regimens, enabling robust estimates in the presence of sparse data.
|
||||
|
||||
The Bayesian model assumes conjugate priors for parameter estimation. For example, the coverage probability \eqn{\theta} for a given antimicrobial regimen is modelled using a Beta distribution as a prior:
|
||||
|
||||
@ -1869,16 +1869,26 @@ Posterior parameter estimates are obtained by combining the prior and likelihood
|
||||
|
||||
\deqn{\theta | y \sim \text{Beta}(\alpha_0 + y, \beta_0 + n - y)}
|
||||
|
||||
Pathogen incidence, representing the proportion of infections caused by different pathogens, is modelled using a Dirichlet distribution, which is the natural conjugate prior for multinomial outcomes. The Dirichlet distribution is parameterised by a vector of concentration parameters \eqn{\alpha}, where each \eqn{\alpha_i} corresponds to a specific pathogen. The prior is typically chosen to be uniform (\eqn{\alpha_i = 1}), reflecting an assumption of equal prior probability across pathogens.
|
||||
|
||||
The posterior distribution of pathogen incidence is then given by:
|
||||
|
||||
\deqn{\text{Dirichlet}(\alpha_1 + n_1, \alpha_2 + n_2, \dots, \alpha_K + n_K)}
|
||||
|
||||
where \eqn{n_i} is the number of infections caused by pathogen \eqn{i} observed in the data. For practical implementation, pathogen incidences are sampled from their posterior using normalised Gamma-distributed random variables:
|
||||
|
||||
\deqn{x_i \sim \text{Gamma}(\alpha_i + n_i, 1)}
|
||||
\deqn{p_i = \frac{x_i}{\sum_{j=1}^K x_j}}
|
||||
|
||||
where \eqn{x_i} represents unnormalised pathogen counts, and \eqn{p_i} is the normalised proportion for pathogen \eqn{i}.
|
||||
|
||||
For hierarchical modelling, pathogen-level effects (e.g., differences in resistance patterns) and regimen-level effects are modelled using Gaussian priors on log-odds. This hierarchical structure ensures partial pooling of estimates across groups, improving stability in strata with small sample sizes. The model is implemented using Hamiltonian Monte Carlo (HMC) sampling.
|
||||
|
||||
Stratified results can be provided based on covariates such as age, sex, and clinical complexity (e.g., prior antimicrobial treatments or renal/urological comorbidities) using \code{dplyr}'s \code{\link[=group_by]{group_by()}} as a pre-processing step before running \code{\link[=wisca]{wisca()}}. In this case, posterior odds ratios (ORs) are derived to quantify the effect of these covariates on coverage probabilities:
|
||||
|
||||
\deqn{\text{OR}_{\text{covariate}} = \frac{\exp(\beta_{\text{covariate}})}{\exp(\beta_0)}}
|
||||
|
||||
By combining empirical data with prior knowledge, WISCA overcomes the limitations
|
||||
of traditional combination antibiograms, offering disease-specific, patient-stratified
|
||||
estimates with robust uncertainty quantification. This tool is invaluable for antimicrobial
|
||||
stewardship programs and empirical treatment guideline refinement.
|
||||
By combining empirical data with prior knowledge, WISCA overcomes the limitations of traditional combination antibiograms, offering disease-specific, patient-stratified estimates with robust uncertainty quantification. This tool is invaluable for antimicrobial stewardship programs and empirical treatment guideline refinement.
|
||||
}
|
||||
|
||||
\examples{
|
@ -223,9 +223,9 @@ Note that for types 2 and 3 (Combination Antibiogram and Syndromic Antibiogram),
|
||||
|
||||
\subsection{Plotting}{
|
||||
|
||||
All types of antibiograms as listed above can be plotted (using \code{\link[ggplot2:autoplot]{ggplot2::autoplot()}} or base \R's \code{\link[=plot]{plot()}} and \code{\link[=barplot]{barplot()}}).
|
||||
All types of antibiograms as listed above can be plotted (using \code{\link[ggplot2:autoplot]{ggplot2::autoplot()}} or base \R's \code{\link[=plot]{plot()}} and \code{\link[=barplot]{barplot()}}). As mentioned above, the numeric values of an antibiogram are stored in a long format as the \link[=attributes]{attribute} \code{long_numeric}. You can retrieve them using \code{attributes(x)$long_numeric}, where \code{x} is the outcome of \code{\link[=antibiogram]{antibiogram()}} or \code{\link[=wisca]{wisca()}}.
|
||||
|
||||
THe outcome of \code{\link[=antibiogram]{antibiogram()}} can also be used directly in R Markdown / Quarto (i.e., \code{knitr}) for reports. In this case, \code{\link[knitr:kable]{knitr::kable()}} will be applied automatically and microorganism names will even be printed in italics at default (see argument \code{italicise}).
|
||||
The outcome of \code{\link[=antibiogram]{antibiogram()}} can also be used directly in R Markdown / Quarto (i.e., \code{knitr}) for reports. In this case, \code{\link[knitr:kable]{knitr::kable()}} will be applied automatically and microorganism names will even be printed in italics at default (see argument \code{italicise}).
|
||||
|
||||
You can also use functions from specific 'table reporting' packages to transform the output of \code{\link[=antibiogram]{antibiogram()}} to your needs, e.g. with \code{flextable::as_flextable()} or \code{gt::gt()}.
|
||||
}
|
||||
@ -233,7 +233,7 @@ You can also use functions from specific 'table reporting' packages to transform
|
||||
\section{Why Use WISCA?}{
|
||||
|
||||
|
||||
WISCA, as outlined by Barbieri \emph{et al.} (\doi{10.1186/s13756-021-00939-2}), stands for Weighted-Incidence Syndromic Combination Antibiogram, which estimates the probability of adequate empirical antimicrobial regimen coverage for specific infection syndromes. This method leverages a Bayesian hierarchical logistic regression framework with random effects for pathogens and regimens, enabling robust estimates in the presence of sparse data.
|
||||
WISCA, as outlined by Bielicki \emph{et al.} (\doi{10.1093/jac/dkv397}), stands for Weighted-Incidence Syndromic Combination Antibiogram, which estimates the probability of adequate empirical antimicrobial regimen coverage for specific infection syndromes. This method leverages a Bayesian hierarchical logistic regression framework with random effects for pathogens and regimens, enabling robust estimates in the presence of sparse data.
|
||||
|
||||
The Bayesian model assumes conjugate priors for parameter estimation. For example, the coverage probability \eqn{\theta} for a given antimicrobial regimen is modelled using a Beta distribution as a prior:
|
||||
|
||||
@ -247,16 +247,26 @@ Posterior parameter estimates are obtained by combining the prior and likelihood
|
||||
|
||||
\deqn{\theta | y \sim \text{Beta}(\alpha_0 + y, \beta_0 + n - y)}
|
||||
|
||||
Pathogen incidence, representing the proportion of infections caused by different pathogens, is modelled using a Dirichlet distribution, which is the natural conjugate prior for multinomial outcomes. The Dirichlet distribution is parameterised by a vector of concentration parameters \eqn{\alpha}, where each \eqn{\alpha_i} corresponds to a specific pathogen. The prior is typically chosen to be uniform (\eqn{\alpha_i = 1}), reflecting an assumption of equal prior probability across pathogens.
|
||||
|
||||
The posterior distribution of pathogen incidence is then given by:
|
||||
|
||||
\deqn{\text{Dirichlet}(\alpha_1 + n_1, \alpha_2 + n_2, \dots, \alpha_K + n_K)}
|
||||
|
||||
where \eqn{n_i} is the number of infections caused by pathogen \eqn{i} observed in the data. For practical implementation, pathogen incidences are sampled from their posterior using normalised Gamma-distributed random variables:
|
||||
|
||||
\deqn{x_i \sim \text{Gamma}(\alpha_i + n_i, 1)}
|
||||
\deqn{p_i = \frac{x_i}{\sum_{j=1}^K x_j}}
|
||||
|
||||
where \eqn{x_i} represents unnormalised pathogen counts, and \eqn{p_i} is the normalised proportion for pathogen \eqn{i}.
|
||||
|
||||
For hierarchical modelling, pathogen-level effects (e.g., differences in resistance patterns) and regimen-level effects are modelled using Gaussian priors on log-odds. This hierarchical structure ensures partial pooling of estimates across groups, improving stability in strata with small sample sizes. The model is implemented using Hamiltonian Monte Carlo (HMC) sampling.
|
||||
|
||||
Stratified results can be provided based on covariates such as age, sex, and clinical complexity (e.g., prior antimicrobial treatments or renal/urological comorbidities) using \code{dplyr}'s \code{\link[=group_by]{group_by()}} as a pre-processing step before running \code{\link[=wisca]{wisca()}}. In this case, posterior odds ratios (ORs) are derived to quantify the effect of these covariates on coverage probabilities:
|
||||
|
||||
\deqn{\text{OR}_{\text{covariate}} = \frac{\exp(\beta_{\text{covariate}})}{\exp(\beta_0)}}
|
||||
|
||||
By combining empirical data with prior knowledge, WISCA overcomes the limitations
|
||||
of traditional combination antibiograms, offering disease-specific, patient-stratified
|
||||
estimates with robust uncertainty quantification. This tool is invaluable for antimicrobial
|
||||
stewardship programs and empirical treatment guideline refinement.
|
||||
By combining empirical data with prior knowledge, WISCA overcomes the limitations of traditional combination antibiograms, offering disease-specific, patient-stratified estimates with robust uncertainty quantification. This tool is invaluable for antimicrobial stewardship programs and empirical treatment guideline refinement.
|
||||
}
|
||||
|
||||
\examples{
|
||||
|
Loading…
Reference in New Issue
Block a user